- Trial phase
- Nonclinical / Preclinical
- Time to market
- KER-206 is at the nonclinical stage. Assuming successful IND-enabling studies, Phase 1 initiation would be at least 12-18 months away. Commercialization, if successful, would be many years away (likely 2030s).
- Why 2/10
- KER-206 is a nonclinical (preclinical) program that was just nominated for further investigation in Q3 2026. There is no scheduled PDUFA date, pivotal readout, or other hard binary catalyst within the next 12 months. The earliest meaningful catalyst would be an IND filing or Phase 1 initiation, which is likely more than a year away.
KER-206 is a preclinical asset with no near-term catalysts. The next meaningful update would likely come when Keros announces plans to file an IND or initiate first-in-human studies, which is probably 12+ months away. For KROS investors, the more immediate value drivers are the Phase 2 rinvatercept data in DMD expected in H1 2027 and Takeda's Phase 3 progress with elritercept.
Price Chart
Executive Summary
KER-206 is a nonclinical (preclinical) ligand trap drug candidate from Keros Therapeutics (NASDAQ: KROS), designed to treat osteoporosis by promoting bone remodeling. It was nominated for further investigation in Q3 2026, with the company reporting that it showed reversal of bone loss in a mouse model of osteoporosis. KER-206 is at the very earliest stage of development, with no clinical trials initiated, no IND filed, and no near-term catalysts. It represents a small, early-stage program within Keros' broader pipeline, which is led by elritercept (KER-050, licensed to Takeda in Phase 3) and rinvatercept (KER-065, in Phase 2 for Duchenne muscular dystrophy).
How It Works
KER-206 is a ligand trap, a type of biologic drug designed to bind to and neutralize specific signaling proteins in the TGF-beta family that regulate bone remodeling. By blocking these signals, it aims to shift the balance toward bone formation, potentially reversing bone loss in conditions like osteoporosis. It is administered as an injectable protein therapy, similar to Keros' other pipeline drugs.
Trial Status
KER-206 was nominated as a development candidate in Q3 2026. It has demonstrated reversal of bone loss in a mouse model of osteoporosis. No human trials have been initiated, and no IND has been filed. The program is in the nonclinical (preclinical) stage.
The Two-Sided Case
Upcoming Catalysts
- No near-term catalysts for KER-206 specifically. The next milestone would be IND-enabling studies and potential IND filing, likely 12+ months away.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Keros Therapeutics, Inc. 8-K KROS ·Originating report